News and Announcements
Collaborate (ASX:CL8) Raises $3.5m, Receives $1m Investment from RACV & Reports Record Cash Receipts
- Published August 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Collaborate Corporation Limited (ASX:CL8) has recently announced the consolidated quarterly cash flow report and business updated for the quarter ended 30 June 2017.
KEY TAKEAWAYS:
- Exercise of 100% of CL80 listed options raising a total of $3,500,295
- Strategic investment of $1 million received from RACV at an issue price of $0.03 per share, a 20% premium to the last closing price prior to issue.
- Collaborate and RACV are working to jointly realise peer-to-peer rental opportunities in the sharing economy in Victoria (for RACV’s 2.1 million members and the wider Victorian market.
- $3.6 million cash held at the end of June 2017, an increase of $3.4 million versus March 2017 Quarter.
- 56% increase in receipts, the June Quarter produced the highest ever cash receipts achieved by the company from its peer-to-peer operations.
- Significant progress with development and launch planning for the Mobilise business.
- Significant progress in incubating a new peer-to-peer business.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
